hCBE 11Alternative Names: Anti-lymphotoxin-beta-receptor-monoclonal-antibody; CBE-11-monoclonal-antibody; hCBE-11; Monoclonal-antibody-CBE-11
Latest Information Update: 13 Jun 2013
At a glance
- Originator Biogen Idec
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 Apr 2013 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
- 01 Jan 2005 Phase-I clinical trials in Solid tumours in USA (unspecified route)